Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of Class Action against Intercept Pharmaceuticals, Inc.

 Shareholder Alert: Bronstein, Gewirtz & Grossman, LLC Notifies Investors of
   Class Action against Intercept Pharmaceuticals, Inc. and Lead Plaintiff
                          Deadline of April 22, 2014

PR Newswire

NEW YORK, Feb. 24, 2014

NEW YORK, Feb. 24, 2014 /PRNewswire/ --Bronstein, Gewirtz & Grossman, LLC
announces that a securities class action has been filed in the United States
District Court for the Southern District of New York on behalf of those who
purchased shares of Intercept Pharmaceuticals, Inc. ("Intercept" or the
"Company") (NasdaqGS: ICPT ), during the period between January 9, 2014 and
January 10, 2014, inclusive (the "Class Period").

The complaint charges Intercept and certain of its executives with violations
of federal securities laws. On January 9 and 10, 2014, Intercept announced
that its Phase 2 trial of its primary drug compound obeticholic acid had been
stopped early based on an interim analysis that showed that the efficacy
endpoint of the trial had been met.

Then, on Friday, January 10, 2014, after the markets closed, the National
Institutes of Health issued a written statement revealing that, while the
efficacy primary endpoint in the study had already been met, participants in
the study who received the drug suffered disproportionate levels of lipid
abnormalities. On this news, Intercept stock dropped from its $445.83 per
share closing price on January 10, 2014, to a closing price of $255.12 per
share on January 14, 2014.

Plaintiff seeks to recover damages on behalf of all Intercept shareholders who
purchased common stock during the Class Period described above.

No Class has yet been certified in the above action. If you wish to review a
copy of the Complaint, to discuss this action, or have any questions, please
contact Peretz Bronstein, Esq. or his Investor Relations Coordinator Eitan
Kimelman of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email
info@bgandg.com. Those who inquire by e-mail are encouraged to include their
mailing address and telephone number. April 22, 2014 is the deadline for
investors to seek a lead plaintiff appointment. Your ability to share in any
recovery doesn't require that you serve as a lead plaintiff.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique. Our
primary expertise is the aggressive pursuit of litigation claims on behalf of
our clients. In addition to representing institutions and other investor
plaintiffs in class action security litigation, the firm's expertise includes
general corporate and commercial litigation, as well as securities
arbitration.Attorney advertising. Prior results do not guarantee similar
outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Eitan Kimelman 212-697-6484
info@bgandg.com

SOURCE Bronstein, Gewirtz & Grossman, LLC

Website: http://www.bgandg.com
 
Press spacebar to pause and continue. Press esc to stop.